HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment

PDS-2™ mentioned in Medical Device And Diagnostic Industry, Apr 19, 2021

PDS-2™ featured in FDA’s “Reflections on a Record Year for Novel Device Innovation Despite COVID-19 Challenges” report, Feb 16, 2021

Dr. Brian Ghoshhajra Details the Significance of the PDS-2™ System in Affecting Progression of HoFH, Dec 5, 2019

American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions May 15 2019

Journal of The American College of Cardiology. 15:55:2727-2735. 2010.  Waksman, Brewer, et al.

Journal of Lipid Research. 50:894-907.2009.  Sacks, Brewer, et al.